Clinical Trials Directory

Trials / Completed

CompletedNCT05440383

A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia

A Phase III Confirmatory Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
287 (actual)
Sponsor
Kissei Pharmaceutical Co., Ltd. · Industry
Sex
Female
Age
20 Years
Healthy volunteers
Not accepted

Summary

Multi-center, randomized, double-blind, parallel-group study to confirm non-inferiority of KLH-2109 to Leuprorelin acetate in uterine fibroids patient with menorrhagia

Conditions

Interventions

TypeNameDescription
DRUGKLH-2109Oral administration
DRUGLeuprorelinSubcutaneous administration

Timeline

Start date
2022-10-11
Primary completion
2024-08-21
Completion
2024-08-21
First posted
2022-06-30
Last updated
2025-03-14

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT05440383. Inclusion in this directory is not an endorsement.

A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia (NCT05440383) · Clinical Trials Directory